Redeye comments on the year-end report and updates our view after financing and distribution of OncoZenge. We have gone through the case again, and there is much that we like with Moberg at this point. Our expectations on the market and the future possibilities of MOB-015 remains bright. We have also updated our model and rating of the company. The new risk-adjusted fair value range is SEK 6 – 32 per share with a motivated risk-adjusted base case of SEK 16 per share.